Stemline Therapeutics Inc (STML) Expected to Post Earnings of -$0.67 Per Share

Equities research analysts forecast that Stemline Therapeutics Inc (NASDAQ:STML) will post earnings per share (EPS) of ($0.67) for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.83) to ($0.50). Stemline Therapeutics posted earnings per share of ($0.69) in the same quarter last year, which would suggest a positive year over year growth rate of 2.9%. The company is expected to report its next earnings results on Wednesday, May 8th.

According to Zacks, analysts expect that Stemline Therapeutics will report full year earnings of ($2.24) per share for the current fiscal year, with EPS estimates ranging from ($2.88) to ($1.63). For the next year, analysts anticipate that the business will post earnings of ($0.55) per share, with EPS estimates ranging from ($1.87) to $1.00. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Stemline Therapeutics.

STML has been the topic of a number of recent research reports. Piper Jaffray Companies reissued an “overweight” rating on shares of Stemline Therapeutics in a report on Wednesday, February 6th. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. ValuEngine raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 4th. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Stemline Therapeutics in a report on Wednesday, December 26th. Finally, BidaskClub raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, December 27th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Stemline Therapeutics currently has a consensus rating of “Buy” and an average price target of $26.00.

In related news, COO Kenneth Hoberman sold 10,557 shares of the company’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $12.05, for a total transaction of $127,211.85. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO David Gionco sold 13,492 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.11, for a total value of $149,896.12. The disclosure for this sale can be found here. Insiders have sold 180,999 shares of company stock worth $2,048,415 in the last ninety days. 14.80% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Hikari Power Ltd acquired a new position in Stemline Therapeutics during the fourth quarter worth $144,000. Point72 Asset Management L.P. grew its holdings in Stemline Therapeutics by 20.9% during the third quarter. Point72 Asset Management L.P. now owns 260,000 shares of the biopharmaceutical company’s stock worth $4,316,000 after acquiring an additional 45,000 shares during the period. Vanguard Group Inc. grew its holdings in Stemline Therapeutics by 1.5% during the third quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock worth $21,215,000 after acquiring an additional 18,487 shares during the period. Polar Capital LLP grew its holdings in Stemline Therapeutics by 12.1% during the fourth quarter. Polar Capital LLP now owns 2,302,666 shares of the biopharmaceutical company’s stock worth $21,875,000 after acquiring an additional 248,616 shares during the period. Finally, BlueMountain Capital Management LLC grew its holdings in Stemline Therapeutics by 175.9% during the third quarter. BlueMountain Capital Management LLC now owns 23,537 shares of the biopharmaceutical company’s stock worth $391,000 after acquiring an additional 15,006 shares during the period. 47.32% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:STML traded down $0.23 during trading on Friday, reaching $12.90. The company had a trading volume of 738,305 shares, compared to its average volume of 697,353. The firm has a market cap of $562.04 million, a P/E ratio of -4.31 and a beta of 1.14. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $20.55.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Recommended Story: What is dollar cost averaging (DCA)?

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.